🔴 Biovie is trading 9.76% down in pre-market after Phase 2 ADDRESS-LC trial missed significance across endpoints

Biovie is trading 9.76% down at $1.85 after its Phase 2 ADDRESS-LC trial failed to achieve statistical significance across all endpoints in the overall population.

• Significant findings were limited to prespecified subgroups and described as hypothesis-generating.
• The company scheduled a September 15, 2026 call to discuss topline results.
• The move follows Biovie’s September 14, 2026 close at $2.05, reversing the prior session’s gain.